Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Overleving PCNSL-patiënten verbeterd, maar oversterfte ouderen houdt aan
dec 2020 | Lymfoom